Minoryx Therapeutics Is A Clinical Stage Biotechnology Company Based In Barcelonaspainwith Additional Facilities In Belgiumfounded In 2011The Company Focuses On Discovering And Developing Innovative Treatments For Severe Orphan Diseases Of The Central Nervous Systemcnsthat Have High Unmet Medical Needs The Company Specializes In Small Molecule Drugswith Its Lead Product Being Leriglitazonemin 102 A Selective Ppar Gamma Agonistleriglitazone Is Primarily Developed For Treating X Linked Adrenoleukodystrophyx Ald A Serious Neurodegenerative Diseasethe Drug Has Shown Promising Results In Preclinical Studies And Has Completed Phase 1 Clinical Trialscurrentlyit Is Involved In Several Clinical Studiesincluding The Advance Studynexus Studyand Calyx Studywhich Are Assessing Its Efficacy In Both Adult And Pediatric Patients With X Aldminoryx Has Raised Over A 120 Million In Funding To Support Its Research And Development Effortsand Its Marketing Authorization Application For Leriglitazone Is Under Review By The European Medicines Agency
No conferences found for this company.
| Company Name | Minoryx Therapeutics Sl |
| Country |
Spain
|
| Address | N/A |
| Telephone | N/A |
| N/A |
